Key statistics dashboard for Silence Therapeutics plc (SLN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver.
Stock Data
| Price | $12.50 |
| Market Cap | $590M |
| Enterprise Value | $518.5M |
| Beta | 1.33 |
| Exchange | NASDAQ |
| Country | GB |
Valuation Multiples
| P/E Ratio | -3.23 |
| Price / Book | 5.03 |
| P/S | 945.77 |
| EV/EBITDA | -8.60 |
| EV/Sales | 844.03 |
| EV/FCF | -12.24 |
| P/FCF | -13.72 |
| Earnings Yield | -30.46% |
| FCF Yield | -7.17% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 51.00% |
| EBIT Margin | -9892.63% |
| EBITDA Margin | -9814.00% |
| Operating Margin | -10880.25% |
| Net Margin | -9759.23% |
| Return on Equity | -106.94% |
| Return on Assets | -56.34% |
| Return on Invested Capital | -71.25% |
| Return on Capital Employed | -71.33% |
Financial Health
| Current Ratio | 7.42 |
| Quick Ratio | 7.42 |
| Cash Ratio | 5.67 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.11% |
| Net Debt / EBITDA | 1.19 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.04 |
| Book Value per share | 2.44 |
| Cash per share | 4.58 |
| FCF per share | -2.69 |
| Tangible Book Value per share | 1.77 |
| Dividend per share | 0.00 |
Related companies: ACIU · ALDX · AMRN · ANRO · CAPR · CTNM · KYTX
Explore sector: Healthcare · Biotechnology
More sections of SLN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks